The discovery that GPR3, GPR6, and GPR12 are molecular targets for CBD provided important mechanistic insight for understanding the therapeutic potential of CBD for various diseases, including Alzheimer’s disease and Parkinson’s disease [20,22,23]. This evidence concerns the gene GPR12 and early-onset autosomal dominant Alzheimer disease.